Search research articles
Contact Us
Filters
Showing results (51-60 of 139) with videos related to
Page
of 14
Sort By:
Annual Review of Biomedical Data Science
|
April 16, 2025
The TITAN-X Platform Integrates Big Data, Artificial Intelligence, Bioinformatics, and Advanced Computational Modeling to Understand Immune Responses and Develop the Next Wave of Precision Medicines
Ryan Baker, Josep Bassaganya-Riera, Nuria Tubau-Juni, et al.
Journal of Medicinal Chemistry
|
December 10, 2016
An N,N-Bis(benzimidazolylpicolinoyl)piperazine (BT-11): A Novel Lanthionine Synthetase C-Like 2-Based Therapeutic for Inflammatory Bowel Disease
Adria Carbo, Richard D Gandour, Raquel Hontecillas, et al.
Inflammatory Bowel Diseases
|
November 7, 2023
Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn's Disease
Nuria Tubau-Juni, Raquel Hontecillas, Andrew J Leber, et al.
Drug and Chemical Toxicology
|
October 26, 2019
Exploratory studies with NX-13: oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1
Andrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.
Inflammatory Bowel Diseases
|
July 12, 2023
Oral Omilancor Treatment Ameliorates Clostridioides difficile Infection During IBD Through Novel Immunoregulatory Mechanisms Mediated by LANCL2 Activation
Nuria Tubau-Juni, Josep Bassaganya-Riera, Andrew J Leber, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
November 8, 2019
Activation of NLRX1 by NX-13 Alleviates Inflammatory Bowel Disease through Immunometabolic Mechanisms in CD4<sup>+</sup> T Cells
Andrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.
Scientific Reports
|
October 7, 2021
First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of LANCL2 pathway in psoriasis
Nuria Tubau-Juni, Raquel Hontecillas, Andrew Leber, et al.
BMC Gastroenterology
|
June 12, 2010
The role of T cell PPAR gamma in mice with experimental inflammatory bowel disease
Amir J Guri, Saroj K Mohapatra, William T Horne, et al.
Frontiers in Immunology
|
March 15, 2018
NLRX1 Modulates Immunometabolic Mechanisms Controlling the Host-Gut Microbiota Interactions during Inflammatory Bowel Disease
Andrew Leber, Raquel Hontecillas, Nuria Tubau-Juni, et al.
Gut Microbes
|
March 5, 2016
Systems-wide analyses of mucosal immune responses to Helicobacter pylori at the interface between pathogenicity and symbiosis
Barbara Kronsteiner, Josep Bassaganya-Riera, Casandra Philipson, et al.
Page
of 14
Search research articles
Search
Showing results (51-60 of 139) with videos related to
Sort By:
Page
of 14
Annual Review of Biomedical Data Science
|
April 16, 2025
The TITAN-X Platform Integrates Big Data, Artificial Intelligence, Bioinformatics, and Advanced Computational Modeling to Understand Immune Responses and Develop the Next Wave of Precision Medicines
Ryan Baker, Josep Bassaganya-Riera, Nuria Tubau-Juni, et al.
Journal of Medicinal Chemistry
|
December 10, 2016
An N,N-Bis(benzimidazolylpicolinoyl)piperazine (BT-11): A Novel Lanthionine Synthetase C-Like 2-Based Therapeutic for Inflammatory Bowel Disease
Adria Carbo, Richard D Gandour, Raquel Hontecillas, et al.
Inflammatory Bowel Diseases
|
November 7, 2023
Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn's Disease
Nuria Tubau-Juni, Raquel Hontecillas, Andrew J Leber, et al.
Drug and Chemical Toxicology
|
October 26, 2019
Exploratory studies with NX-13: oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1
Andrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.
Inflammatory Bowel Diseases
|
July 12, 2023
Oral Omilancor Treatment Ameliorates Clostridioides difficile Infection During IBD Through Novel Immunoregulatory Mechanisms Mediated by LANCL2 Activation
Nuria Tubau-Juni, Josep Bassaganya-Riera, Andrew J Leber, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
November 8, 2019
Activation of NLRX1 by NX-13 Alleviates Inflammatory Bowel Disease through Immunometabolic Mechanisms in CD4<sup>+</sup> T Cells
Andrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.
Scientific Reports
|
October 7, 2021
First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of LANCL2 pathway in psoriasis
Nuria Tubau-Juni, Raquel Hontecillas, Andrew Leber, et al.
BMC Gastroenterology
|
June 12, 2010
The role of T cell PPAR gamma in mice with experimental inflammatory bowel disease
Amir J Guri, Saroj K Mohapatra, William T Horne, et al.
Frontiers in Immunology
|
March 15, 2018
NLRX1 Modulates Immunometabolic Mechanisms Controlling the Host-Gut Microbiota Interactions during Inflammatory Bowel Disease
Andrew Leber, Raquel Hontecillas, Nuria Tubau-Juni, et al.
Gut Microbes
|
March 5, 2016
Systems-wide analyses of mucosal immune responses to Helicobacter pylori at the interface between pathogenicity and symbiosis
Barbara Kronsteiner, Josep Bassaganya-Riera, Casandra Philipson, et al.
Page
of 14